Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion.
OBJECTIVE
To evaluate the effect of intravitreal triamcinolone acetonide (IVTA) treatment on serous macular detachment in patients with central retinal vein occlusion (CRVO).


METHODS
Ten eyes of 10 patients with CRVO (6 men and 4 women; age range, 54-78 years) made up the study population. The eligibility criteria for this study included clinically and angiographically detectable cystoid macular edema (CME) in which the presence of serous macular detachment was documented by optical coherence tomography (OCT). After IVTA (4 mg/0.1 mL) injection, visual and anatomical responses were observed.


RESULTS
In all eyes, after IVTA injection, CME and serous macular detachment regressed. At 3 months and 6 months, CME and serous macular detachment had recurred in 4 (40%) and 5 eyes (50%), respectively. Patients with recurrence were retreated. No eyes lost vision at 1 month, and all eyes had improvement. At 3 months, no eyes had lost vision from baseline, and 7 eyes (70%) had improvement. At 6 months, again no eyes had lost vision from baseline, and 6 eyes (60%) maintained improved visual acuity.


CONCLUSIONS
Our study shows that IVTA is effective treatment for serous macular detachment in patients with CRVO.
Karacorlu
Murat
M
Istanbul Retina Institute, Inc., Istanbul, Turkey. retina@pobox.com
Karacorlu
Serra Arf
SA
Ozdemir
Hakan
H
Senturk
Fevzi
F
D000368:Aged; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide